Prescient Therapeutics hopes to accelerate bid for US FDA study approval for targeted therapy PTX-100
Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results...
Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results...
Telix Pharma (ASX:TLX) announced the US FDA has approved a supplementary New Drug Application (sNDA) for Illuccix,...
The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of...
Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders...
Stockhead’s Year in Review video series is a yearly wrap up address from company leaders...
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings...
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously...
Prescient Therapeutics (ASX: PTX) featured in the ‘Investor Guide for Health & Biotech’ by The...
Prescient has unveiled the latest technology in its cancer-fighting portfolio CellPryme-A at the 7th annual CAR-TCR...
There are many foundations and charities which aim to tackle health conditions through funding medical...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.